R&D evolves rapidly—especially in the past few years. Therapies are getting more sophisticated across cell and gene and other novel platforms, and clinical trial design and execution are, too. Between decentralized studies, data science, site operationalization and other developments, sponsors have more opportunities to set their products on the best path forward.
At the same time, this evolving trial landscape requires an evolving approach to pipelines, processes and people.
This playbook sheds light on why life science companies must be agile and open to change management, not just when sourcing solutions but also when finding the right support to see them through. The playbook touches on: